Study of AMT-110 in patients with Sanfilippo B syndrome
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 04 Apr 2016
At a glance
- Drugs AMT 110 (Primary)
- Indications Mucopolysaccharidosis III
- Focus Adverse reactions; Therapeutic Use
- 04 Apr 2016 According to a media release, uniQure expects to present 30-month follow-up data from four patients in early 2017.
- 19 Sep 2015 Results presented at the European Society of Gene and Cell Therapy (ESGCT) and Finnish Society of Gene Therapy (FSGT) Collaborative Congress, as per Uniqure media release.
- 19 Sep 2015 Positive top-line results published in Uniqure media release.